Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352714 · ClinicalTrials.gov registry record · Phase 4
Study of Pain Control With Hormonal IUS Insertion
A Phase 4 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
NCT02352714: Completed Phase 4 study, sponsored by Children's Hospital of Philadelphia.
NCT02352714 is a Phase 4 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 98 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02352714, a Phase 4 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
Study Summary
This study aims to compare pain during insertion of the Skyla® IUS using a 100mm visual analog scale (VAS) among 92 young women aged 14 to 22 years randomized to receive a paracervical (n=46) block versus a sham paracervical block (n=46).
Primary Outcome
The primary outcome will be assessed using a visual analogue scale (VAS). Assessment will occur at the time of the insertion of the IUS device. The IUS will be placed according to manufacturer's recommendation.
Interventions
- DRUG Paracervical Nerve Block
- DRUG Sham Paracervical Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
What the finished NCT02352714 record still lists
NCT02352714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Paracervical Nerve Block is the first listed.
NCT02352714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02352714 about?
NCT02352714 is a clinical study titled "Study of Pain Control With Hormonal IUS Insertion". This study aims to compare pain during insertion of the Skyla® IUS using a 100mm visual analog scale (VAS) among 92 young women aged 14 to 22 years randomized to receive a paracervical (n=46) block versus a sham paracervical block (n=46).
What is the current status of trial NCT02352714?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2015-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02352714?
The interventions under investigation include: Paracervical Nerve Block (DRUG), Sham Paracervical Block (DRUG).
Who is sponsoring clinical trial NCT02352714?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02352714's enrollment target sits among peer trials
98 854th of 2000 higher than 1,140 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia